Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer

This study has been terminated.
(Incyte suspended development of the compound.)
Sponsor:
Information provided by (Responsible Party):
Incyte Corporation
ClinicalTrials.gov Identifier:
NCT00864175
First received: January 26, 2009
Last updated: January 20, 2012
Last verified: January 2012
  Purpose

This is a single arm, modified dose escalation, open label trial with the objectives of: (1) Determining a safe optimal dose of INCB007839 in combination with trastuzumab and docetaxel (2) Determining clinical efficacy and safety of INCB007839 in combination with trastuzumab and docetaxel.


Condition Intervention Phase
Metastatic Breast Cancer
Drug: INCB007839 and trastuzumab
Drug: INCB007839 and Docetaxel
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1/2, Modified Dose Escalation, Open Label Trial to Determine the Therapeutic Effect and Safety of INCB007839 Combined With Trastuzumab in Patients With Previously Untreated HER2 Positive Metastatic Breast Cancer

Resource links provided by NLM:


Further study details as provided by Incyte Corporation:

Primary Outcome Measures:
  • Overall response rate (complete + partial response) using RECIST (Response Evaluation Criteria in Solid Tumor) criteria [ Time Frame: Day 1 of each completed subsequent 21-day treatment cycle and the End of Study Visit. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To determine the plasma pharmacokinetic (PK) profile of INCB007839 and trastuzumab when given in combination [ Time Frame: Monthly ] [ Designated as safety issue: No ]

    For Cycle 1, PK samples to be collected on Day 8 and Day 15 at pre-dose the morning dose of INCB007839. For Cycles 2, 3 and 4, PK will be collected as a single sample, obtained at pre-dose, on Day 1. PK samples will not be collected at Cycle 5 or later.

    o. For Cycle 1, PD samples to be collected at time of screening and at pre-dose on Day 1, Day



Enrollment: 68
Study Start Date: July 2007
Study Completion Date: October 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment A - INCB007839 and Trastuzumab

INCB007839 100 mg BID and trastuzumab

In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1.

Drug: INCB007839 and trastuzumab
100 mg BID
Experimental: Treatment B - INCB007839 and Trastuzumab

INCB007839 200 mg BID and trastuzumab

In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1.

Drug: INCB007839 and trastuzumab
200 mg BID
Experimental: Treatment C - INCB007839 and Trastuzumab

INCB007839 300 mg BID and trastuzumab

In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1.

Drug: INCB007839 and trastuzumab
300 mg BID
Experimental: Treatment D - INCB007839 and Docetaxel
INCB007839 300mg BID with docetaxel
Drug: INCB007839 and Docetaxel
300 mg BID

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed metastatic breast carcinoma that is HER2 positive
  • Measurable disease as defined by the RECIST criteria
  • Life expectancy greater than or equal to 6 months
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

  • Received any anticancer medications in the 28 days prior to enrollment into this study
  • Received any anticancer medications for cancers other than breast cancer within 6 months prior to enrollment in this study.
  • History of deep venous thrombosis within the last year
  • Contraindication to low dose warfarin therapy
  • Clinically significant cardiomyopathy
  • Prior treatment with INCB007839 or trastuzumab or lapatinib
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00864175

Locations
India
Vishakhapattanam, Andhra Pradesh, India
New Delhi, Ansari Nagar, India
Mangalore, Attavar, India
Idgah Hills, Bhopal, India
Bangalore, Karnataka, India
Hyderabaad, Punjagutta, India
Bangalore, Ram Nagar, India
Delhi, Rohini, India
Delhi, Vasundhara Enclave, India
Nasik, India
Pune, India
West Bengal, India
Sponsors and Collaborators
Incyte Corporation
Investigators
Study Director: Bijyoyesh Mookerjee, MD Incyte Corporation
  More Information

No publications provided

Responsible Party: Incyte Corporation
ClinicalTrials.gov Identifier: NCT00864175     History of Changes
Other Study ID Numbers: INCB 7839-202
Study First Received: January 26, 2009
Last Updated: January 20, 2012
Health Authority: United States: Food and Drug Administration
India: Drugs Controller General of India

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Docetaxel
Trastuzumab
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 16, 2014